Gender differences in cardiovascular drugs

Cardiovascular Drugs and Therapy

Volumn 29, Issue 4, 2015, Pages 403-410

  Stolarz, Amanda J ^a   Rusch, Nancy J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cardiovascular; Drugs; Gender; Medications; Pharmacokinetics; Side effects; Therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; VASODILATOR AGENT;

ARTICLE; DIGOXIN BLOOD LEVEL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; MALE; PRIORITY JOURNAL; QT INTERVAL; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT; SEXUAL DEVELOPMENT;

CARDIOVASCULAR AGENTS; HUMANS; SEX CHARACTERISTICS;

EID: 84943362368     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6611-8     Document Type: Article

References (82)

1. Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Women’s Health. 2014;23(2):112-9
2. Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Manfrini O, et al. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J. 2011;32:1337-44
3. Johansen, ME Hefner JL, Foraker RE. Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. Am J Cardiol. 2015
4. Rademaker M. Do women havemore adverse drug reactions? AmJ Clin Dermatol. 2001;2(6):349-51
5. Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun Rev. 2012;11(6-7):A479-85
6. Whitley HP, LindseyW. Sex-based differences in drug activity. Am Fam Physician. 2009;80(11):1255-8
7. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. JWomen’s Health. 2005;14(1):19-29
8. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006;5(5): 425-38
9. Kimura T, Higaki K. Gastrointestinal transit and drug absorption. Biol Pharm Bull. 2002;25(2):149-64
10. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal, and formulation interactions influencing drug absorption after oral administration. Clin Implications Clin Pharmacokinet. 1999;36(3): 233-54
11. Mojaverian P, Rocci ML Jr., Conner DP, Abrams WB, Vlasses PH. Effect of food on the absorption of enteric coated aspirin: correlation with gastric residence time. Clin Pharmacol Ther. 1987;41(1): 11-7
12. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82(1):87-96
13. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51:169-73
14. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Populationbased investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol. 1997;37(2):92-100
15. Mattison D. Cardiovascular medications during pregnancy. In: Clinical Pharmacology During Pregnancy, Mattison D. (ed), Academic Press, 2013, Chpt 18, pp 275-294
16. Desai H, Hollingsworth PW, Chugh AR. Statins and aspirin: do they really work in women? Am J Cardiovasc Drugs. 2015. doi: 10.1007/s40256-015-0111x
17. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118
18. Stead LG, Vaidyanathan L, Kumar G, Fellolio MF, Brown RD, Suravaram S, et al. Statins in ischemic stroke: just low-density lipoprotein lowering or more? J Stroke Cerebrovasc Dis. 2009;18(2):124-7
19. Pawelczyk M, Chmielewski H, Kaczorowska B, Przybyla M, Baj Z. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke. Arch Med Sci. 2015;11(1):115-21
20. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18:1519-30
21. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Antiinflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63:12-23
22. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172(2):144-52
23. Bang CN, Okin PM. Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Curr Cardiol Rep. 2014;16(3): 461-4
24. Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CP, Group TS. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes. 2011;4(3):328-36
25. Basili S, Raparelli V, Proietti M, Tanzilli G, Franconi F. The impact of sex and gender on the efficacy of antiplatelet therapy: the female perspective. J Atheroscler Thromb. 2015;22:109-25
26. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-18
27. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306-13
28. Meyer DM, Eastwood JA, Copton MP, Gylys K, Zivin JA, Ovbiagele B. Sex differences in antiplatelet response in ischemic stroke. J Womens Health (Lond). 2011;7(4):465-74
29. Buchanan MR Rischke JA, Butt R, Turpie AG, Hirsh J, Rosenfeld J., et al. The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Thromb Res. 1983;29:125-39
30. Samad Z, Boyle S, Ersboll M, Vora AN, Zhang Y, Becker RC, et al. Sex differences in platelet reactivity and cardiovascular and pyschological response to mental stress in patients with stable ischemic heart disease. J Am Coll Cardiol. 2014;64:1669-78
31. Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM. Effect of genetic variations in platelet glycoproteins Iba and VI on the risk of coronary heart disease events in postmenopausal women taking hormone therapy. Blood. 2007;109(5):1862-9
32. Nakano Y, Oshima T, Ozono R, Ueda A, Oue Y, Matsuura H, et al. Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca2+ influx and raising cyclic adenosine monophosphate. Cardiovasc Res. 2002;53:634-41
33. Miller VM, Jayachandran M, Hashimoto K, Heit JA, Owen WG. Estrogen, inflammation, and platelet phenotype. Gend Med. 2008;5(Suppl A):S91-102
34. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197-207
35. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2012;104:471-84
36. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Circulation. 1996;93: 870-8
37. Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I Investigators. JAMA. 1996;275(10):777-82
38. Woodfield SL, Lundergan CF, Reiner JS, Thompson MA, Rohrbeck SC, Deychak Y, et al. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol. 1997;29:35-42
39. Van deWerf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, et al. Fox NL; ASSENT-2 Investigators. Assessment of the safety and efficacy of a new thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrinspecific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;22:2253-61
40. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simons M, et al. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) I Investigators. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation. 1997;95:2508-16
41. Gheorghiade M, Adams KF, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959-64
42. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-33
43. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403-11
44. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for themanagement of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239
45. Helfand M, Peterson K, Christensen V, Dana T, Thakurta S. Drug class review: Beta adrenergic blockers: final report update 4. Portland (OR): Oregon Health & Science University; 2009. http://www.ncbi.nlm.nih.gov/books/NBK47172/
46. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharm Ther. 1999;66(6):594-601
47. Cocco G, Chu D. The anti-ischemic effect of metoprolol in patients with chronic angina pectoris is gender-specific. Cardiology. 2006;106:147-53
48. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERITHF). Lancet. 1999;353: 2001-7
49. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-55
50. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the cardiac insufficiency bisoprolol study (CIBIS II). Circulation. 2001;103:375-80
51. CIBISII. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13
52. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol extended-release randomized intervention trial in heart failure (MERIT-HF). Circulation. 2000;105: 1585-91
53. Leenhardt A, Coumel P, Slama R. Torsades de pointes. J Cardiovasc Electrophysiol. 1992;3:281-92
54. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndrome: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31:115-72
55. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA Clin Cardiol. 1993;270(21): 2590-7
56. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d, l-sotalol. Circulation. 1996;94:2535-41
57. Merri M, Benhorin J, Alberti M, Locati E, Moss A. Electrocardiographic quantitation of ventricular repolarization. Circulation. 1989;80:1301-8
58. Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J. 1997;18:1000-6
59. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol. 1992;8:690-5
60. Sadlak T, Shufelt C, Iribarren C, Bairey Merz CN. Sex hormones and the QT interval: a review. J Women’s Health. 2012;21(9):933-41
61. Nakagawa M, Ooie T, Takahashi N, Taniguchi Y, Anan F, Yonemochi H, et al. Influence of menstrual cycle on QT interval dynamics. PACE. 2006;29:607-13
62. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL, Druginduced QT prolongation in women during the menstrual cycle. JAMA. 2001;285:1322-6
63. Fazio G, Vernuccio F, Grutta G, Lo RG. Drugs to be avoided in patients with long QT syndrome: focus on the anaesthesiological management. World J Cardiol. 2013;5(4):87-93
64. Thompson KA, Murray JJ, Blair IA, Woosley RL, Roden DM. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther. 1988;43:636-42
65. Darpo B, Karnad DR, Balilini F, Florlan J, Garnett CE, Korthari S, et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2013;77(3):522-31
66. Nakagawa M, Ooie T, Ou B, Ichinose M, Takahashi M, Hara M, et al. Gender differences in autonomic modulation of ventricular repolarization in humans. J Cardiovasc Electrophysiol. 2005;16: 278-84
67. Conrath CE, Wilde AAM, Jongbloed RJE, Alders M, van Langen IM, van Tintelen JP, et al. Gender differences in the long QT syndrome: effects of β-adrenocepter blockade. Cardiovasc Res. 2002;53:770-6
68. Dadashzadeha S, Javadiana B, Sadeghianb S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in humans. Biopharm Drug Dispos. 2006;27:329-34
69. Abad-Santos F, Novalbos J, Gálvez-Múgica MA, Gallego-Sandín S, Almeida S, Vallée F, et al. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res. 2005;51(5):445-52
70. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol. 1996;77(9):713-22
71. Spratt KA. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol. 1997;79(6):843-4
72. Vree TB, Dammers E, Valducci R. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. Int J Clin Pharmacol Ther. 2004;42(8):463-72
73. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;8, CD009096
74. Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertens. 2015;65(5):1033-40
75. Ljungman C, Kahan T, Schioler L, Hjerpe P, Hasselstrom J, Wettermark B, et al. Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD). J Am Soc Hypertens. 2014;8(12):882-90
76. Ljungman C, Kahan T, Schiöler L, Hjerpe P, Wettermark B, Boström KB, Manhem K. Antihypertensive treatment and control according to gender, education, country of birth and psychiatric disorder: the Swedish Primary Care Cardiovascular Database (SPCCD). J Hum Hyperten. 2014
77. Li DK, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011;343:d5931
78. Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol. 2011;31(6):465-72
79. Moretti ME, Caprara D, Drehuta I, Yeung E, Cheung S, Federico L, Koren G. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int. 2012
80. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-51
81. Os I, Bratland B, Dahl€of B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens. 1994;7:1012-5
82. Barber J, McKeever TM, McDowell SE, Clayton JA, Ferner RE, Gordon RD, et al. A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation? Br J Clin Pharmacol. 2015;79(4):566-77